The Week in Review: June 8 – June 15, 2018

Friday, June 15, 2018 News Recap: Canada: Canada is facing a tsunami of liver disease and cancer: U of T expert – The Conversation with U of T's Dr. Morris Sherman. Deaths from liver cancer in Canada have doubled over the past 25 years. And to make matters worse, there’s an epidemic of liver cancer on the horizon if action isn’t taken soon. While less people are dying from most major cancers – such as breast cancer and lung cancer – liver cancer (...

DAA Therapy Outcomes in HCV-Infected Transplant Candidates After Organ Delisting

Hepatitis C virus (HCV) antiviral therapy in liver transplant candidates with decompensated cirrhosis may result in long-term improvement in liver function, giving as many as 1 in 3 patients the possibility of being taken off the transplant list, according to a study published in Liver International. Many people infected with HCV who have decompensated cirrhosis are on the waiting list for liver transplantation. A previous study by the European Liver and

The Week in Review: March 16 – March 23, 2018

Friday, March 23, 2018 News Recap: Northern Vancouver Island VIRAL HEPATITIS Outreach Roadshow Trip 2018 SlideShow.  Our team of volunteers has just return from a week of outreach on Vancouver Island’s north end, and we have put together few slideshows to tell you the story. There will be more images in the next few days, but check out what we have so far! A heartfelt thanks to Cheryl, Leon and Rosemary for doing this. Novel score predicts DAA ben...

Novel score predicts DAA benefit in patients with HCV, decompensated cirrhosis

Researchers have developed a predictive score that quantifies the potential benefits of direct-acting antiviral therapy for patients with hepatitis C and decompensated cirrhosis, according to recently published data. Five factors – BMI, hepatic encephalopathy, ascites, serum albumin and alanine aminotransferase levels – contribute to the novel BE3A score. “There are certain hepatitis C medications that you cannot use in patients with decompensation becaus

New Hep C Recommendations Target Unique Populations

Updated guidelines from the American Association for the Study of Liver Diseases (AASLD) and Infectious Diseases Society of America (IDSA) for the treatment of hepatitis C have identified preferred regimens for patients with decompensated cirrhosis and for other unique populations, such as those with renal impairment. The recommendations have been divided into a list of variables, including genotype, status of liver function, prior treatment and eligibi